Positron Corp.

June 13, 2012 — Positron Corp. announced completion of its first strontium validation effort in May 2012, when Manhattan Isotope Technology (MIT), a Positron subsidiary, successfully processed strontium.

February 24, 2012 — Positron Corp., through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT), announced it had received its first shipment of strontium-82 (Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France.

January 20, 2012 – Nuclear cardiology imaging company Positron Corp. this week acquired Manhattan Isotope Technology LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3.5 million based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.

Despite its first commercial appearance in the late 1970s, positron emission tomograpnhy (PET) did not begin gaining widespread acceptance as a viable clinical technology until the mid-1990s. This was after it gained approval for reimbursement and radiopharmaceuticals for PET became more widely available.

November 12, 2009 - Positron Corp. predicts an industry wide demand for cardiac PET imaging, as a result of the Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule increasing Cardiac PET reimbursement by 20 percent, while reducing coverage for SPECT by 36 percent.